nodes	percent_of_prediction	percent_of_DWPC	metapath
Dexmedetomidine—ADRA1B—vas deferens—urinary bladder cancer	0.108	0.425	CbGeAlD
Dexmedetomidine—CYP1A2—urine—urinary bladder cancer	0.0125	0.0491	CbGeAlD
Dexmedetomidine—CYP2E1—urine—urinary bladder cancer	0.0113	0.0442	CbGeAlD
Dexmedetomidine—ADRA1D—prostate gland—urinary bladder cancer	0.00946	0.0371	CbGeAlD
Dexmedetomidine—CYP2D6—urine—urinary bladder cancer	0.00891	0.035	CbGeAlD
Dexmedetomidine—ADRA1D—epithelium—urinary bladder cancer	0.00695	0.0273	CbGeAlD
Dexmedetomidine—ADRA1B—renal system—urinary bladder cancer	0.00659	0.0259	CbGeAlD
Dexmedetomidine—ADRA1D—urethra—urinary bladder cancer	0.00633	0.0249	CbGeAlD
Dexmedetomidine—ADRA2C—prostate gland—urinary bladder cancer	0.00518	0.0203	CbGeAlD
Dexmedetomidine—ADRA1D—female reproductive system—urinary bladder cancer	0.00516	0.0203	CbGeAlD
Dexmedetomidine—ADRA2C—seminal vesicle—urinary bladder cancer	0.00438	0.0172	CbGeAlD
Dexmedetomidine—ADRA2A—prostate gland—urinary bladder cancer	0.00413	0.0162	CbGeAlD
Dexmedetomidine—CYP2E1—prostate gland—urinary bladder cancer	0.00404	0.0159	CbGeAlD
Dexmedetomidine—ADRA2C—renal system—urinary bladder cancer	0.00353	0.0139	CbGeAlD
Dexmedetomidine—ADRA2A—seminal vesicle—urinary bladder cancer	0.00349	0.0137	CbGeAlD
Dexmedetomidine—ADRA2C—urethra—urinary bladder cancer	0.00346	0.0136	CbGeAlD
Dexmedetomidine—CYP2E1—seminal vesicle—urinary bladder cancer	0.00342	0.0134	CbGeAlD
Dexmedetomidine—CYP1A1—epithelium—urinary bladder cancer	0.00326	0.0128	CbGeAlD
Dexmedetomidine—SLC6A2—female reproductive system—urinary bladder cancer	0.00319	0.0125	CbGeAlD
Dexmedetomidine—CYP1A2—renal system—urinary bladder cancer	0.00306	0.012	CbGeAlD
Dexmedetomidine—CYP1A1—renal system—urinary bladder cancer	0.00302	0.0119	CbGeAlD
Dexmedetomidine—CYP1A1—urethra—urinary bladder cancer	0.00297	0.0116	CbGeAlD
Dexmedetomidine—ADRA2A—urethra—urinary bladder cancer	0.00276	0.0109	CbGeAlD
Dexmedetomidine—CYP2E1—renal system—urinary bladder cancer	0.00275	0.0108	CbGeAlD
Dexmedetomidine—CYP2E1—urethra—urinary bladder cancer	0.0027	0.0106	CbGeAlD
Dexmedetomidine—ADRA2C—vagina—urinary bladder cancer	0.00255	0.01	CbGeAlD
Dexmedetomidine—CYP1A1—female reproductive system—urinary bladder cancer	0.00242	0.0095	CbGeAlD
Dexmedetomidine—ADRA2A—female reproductive system—urinary bladder cancer	0.00225	0.00885	CbGeAlD
Dexmedetomidine—CYP2E1—female reproductive system—urinary bladder cancer	0.00221	0.00866	CbGeAlD
Dexmedetomidine—CYP1A1—vagina—urinary bladder cancer	0.00219	0.00859	CbGeAlD
Dexmedetomidine—CYP2D6—renal system—urinary bladder cancer	0.00218	0.00856	CbGeAlD
Dexmedetomidine—ADRA2A—vagina—urinary bladder cancer	0.00204	0.00801	CbGeAlD
Dexmedetomidine—SLC6A2—lymph node—urinary bladder cancer	0.00187	0.00733	CbGeAlD
Dexmedetomidine—CYP2D6—female reproductive system—urinary bladder cancer	0.00175	0.00686	CbGeAlD
Dexmedetomidine—ADRA2C—lymph node—urinary bladder cancer	0.00165	0.00649	CbGeAlD
Dexmedetomidine—CYP1A1—lymph node—urinary bladder cancer	0.00141	0.00556	CbGeAlD
Dexmedetomidine—ADRA2A—lymph node—urinary bladder cancer	0.00132	0.00518	CbGeAlD
Dexmedetomidine—Arrhythmia—Cisplatin—urinary bladder cancer	0.000943	0.00167	CcSEcCtD
Dexmedetomidine—Blood urea increased—Doxorubicin—urinary bladder cancer	0.000943	0.00167	CcSEcCtD
Dexmedetomidine—Abnormal vision—Epirubicin—urinary bladder cancer	0.000942	0.00166	CcSEcCtD
Dexmedetomidine—Sepsis—Epirubicin—urinary bladder cancer	0.000937	0.00165	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000937	0.00165	CcSEcCtD
Dexmedetomidine—Tachycardia—Thiotepa—urinary bladder cancer	0.000934	0.00165	CcSEcCtD
Dexmedetomidine—Malnutrition—Cisplatin—urinary bladder cancer	0.000919	0.00162	CcSEcCtD
Dexmedetomidine—Anaemia—Gemcitabine—urinary bladder cancer	0.000912	0.00161	CcSEcCtD
Dexmedetomidine—Renal failure acute—Methotrexate—urinary bladder cancer	0.000907	0.0016	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Epirubicin—urinary bladder cancer	0.000901	0.00159	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Etoposide—urinary bladder cancer	0.000898	0.00159	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.000897	0.00158	CcSEcCtD
Dexmedetomidine—Anaemia—Fluorouracil—urinary bladder cancer	0.000896	0.00158	CcSEcCtD
Dexmedetomidine—Pulmonary oedema—Doxorubicin—urinary bladder cancer	0.00089	0.00157	CcSEcCtD
Dexmedetomidine—Angiopathy—Etoposide—urinary bladder cancer	0.000878	0.00155	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000872	0.00154	CcSEcCtD
Dexmedetomidine—Abnormal vision—Doxorubicin—urinary bladder cancer	0.000872	0.00154	CcSEcCtD
Dexmedetomidine—Chills—Etoposide—urinary bladder cancer	0.000868	0.00153	CcSEcCtD
Dexmedetomidine—Sepsis—Doxorubicin—urinary bladder cancer	0.000867	0.00153	CcSEcCtD
Dexmedetomidine—Hypertension—Gemcitabine—urinary bladder cancer	0.000852	0.0015	CcSEcCtD
Dexmedetomidine—Somnolence—Thiotepa—urinary bladder cancer	0.000851	0.0015	CcSEcCtD
Dexmedetomidine—Anaemia—Cisplatin—urinary bladder cancer	0.00085	0.0015	CcSEcCtD
Dexmedetomidine—Renal failure acute—Epirubicin—urinary bladder cancer	0.000849	0.0015	CcSEcCtD
Dexmedetomidine—Convulsion—Fluorouracil—urinary bladder cancer	0.00084	0.00148	CcSEcCtD
Dexmedetomidine—Blood alkaline phosphatase increased—Doxorubicin—urinary bladder cancer	0.000834	0.00147	CcSEcCtD
Dexmedetomidine—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.00083	0.00147	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000826	0.00146	CcSEcCtD
Dexmedetomidine—Constipation—Thiotepa—urinary bladder cancer	0.000818	0.00144	CcSEcCtD
Dexmedetomidine—Pain—Thiotepa—urinary bladder cancer	0.000818	0.00144	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Epirubicin—urinary bladder cancer	0.000803	0.00142	CcSEcCtD
Dexmedetomidine—Infection—Gemcitabine—urinary bladder cancer	0.0008	0.00141	CcSEcCtD
Dexmedetomidine—Confusional state—Fluorouracil—urinary bladder cancer	0.000798	0.00141	CcSEcCtD
Dexmedetomidine—Convulsion—Cisplatin—urinary bladder cancer	0.000797	0.00141	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000789	0.00139	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000788	0.00139	CcSEcCtD
Dexmedetomidine—Infection—Fluorouracil—urinary bladder cancer	0.000786	0.00139	CcSEcCtD
Dexmedetomidine—Renal failure acute—Doxorubicin—urinary bladder cancer	0.000786	0.00139	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000783	0.00138	CcSEcCtD
Dexmedetomidine—Anxiety—Cisplatin—urinary bladder cancer	0.00078	0.00138	CcSEcCtD
Dexmedetomidine—Anaemia—Etoposide—urinary bladder cancer	0.000778	0.00137	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000778	0.00137	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000775	0.00137	CcSEcCtD
Dexmedetomidine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000773	0.00136	CcSEcCtD
Dexmedetomidine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000757	0.00134	CcSEcCtD
Dexmedetomidine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000757	0.00134	CcSEcCtD
Dexmedetomidine—Hypotension—Gemcitabine—urinary bladder cancer	0.000752	0.00133	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000745	0.00132	CcSEcCtD
Dexmedetomidine—Infection—Cisplatin—urinary bladder cancer	0.000745	0.00132	CcSEcCtD
Dexmedetomidine—Hypoglycaemia—Doxorubicin—urinary bladder cancer	0.000743	0.00131	CcSEcCtD
Dexmedetomidine—Hypotension—Fluorouracil—urinary bladder cancer	0.00074	0.00131	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000735	0.0013	CcSEcCtD
Dexmedetomidine—Tachycardia—Cisplatin—urinary bladder cancer	0.000732	0.00129	CcSEcCtD
Dexmedetomidine—Convulsion—Etoposide—urinary bladder cancer	0.00073	0.00129	CcSEcCtD
Dexmedetomidine—Hypertension—Etoposide—urinary bladder cancer	0.000727	0.00128	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000725	0.00128	CcSEcCtD
Dexmedetomidine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000718	0.00127	CcSEcCtD
Dexmedetomidine—Somnolence—Gemcitabine—urinary bladder cancer	0.000716	0.00126	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000714	0.00126	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000706	0.00125	CcSEcCtD
Dexmedetomidine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000706	0.00125	CcSEcCtD
Dexmedetomidine—Somnolence—Fluorouracil—urinary bladder cancer	0.000704	0.00124	CcSEcCtD
Dexmedetomidine—Hypotension—Cisplatin—urinary bladder cancer	0.000701	0.00124	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000695	0.00123	CcSEcCtD
Dexmedetomidine—Confusional state—Etoposide—urinary bladder cancer	0.000693	0.00122	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000691	0.00122	CcSEcCtD
Dexmedetomidine—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.00069	0.00122	CcSEcCtD
Dexmedetomidine—Constipation—Gemcitabine—urinary bladder cancer	0.000688	0.00122	CcSEcCtD
Dexmedetomidine—Pain—Gemcitabine—urinary bladder cancer	0.000688	0.00122	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000683	0.00121	CcSEcCtD
Dexmedetomidine—Infection—Etoposide—urinary bladder cancer	0.000683	0.00121	CcSEcCtD
Dexmedetomidine—Abdominal distension—Epirubicin—urinary bladder cancer	0.000682	0.0012	CcSEcCtD
Dexmedetomidine—Pain—Fluorouracil—urinary bladder cancer	0.000677	0.0012	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000673	0.00119	CcSEcCtD
Dexmedetomidine—Tachycardia—Etoposide—urinary bladder cancer	0.000671	0.00118	CcSEcCtD
Dexmedetomidine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000669	0.00118	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000665	0.00117	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000663	0.00117	CcSEcCtD
Dexmedetomidine—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.00066	0.00117	CcSEcCtD
Dexmedetomidine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000655	0.00116	CcSEcCtD
Dexmedetomidine—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000653	0.00115	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000652	0.00115	CcSEcCtD
Dexmedetomidine—Pneumonia—Methotrexate—urinary bladder cancer	0.000649	0.00115	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000648	0.00114	CcSEcCtD
Dexmedetomidine—Hypotension—Etoposide—urinary bladder cancer	0.000642	0.00113	CcSEcCtD
Dexmedetomidine—Pain—Cisplatin—urinary bladder cancer	0.000642	0.00113	CcSEcCtD
Dexmedetomidine—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00064	0.00113	CcSEcCtD
Dexmedetomidine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000636	0.00112	CcSEcCtD
Dexmedetomidine—Dizziness—Thiotepa—urinary bladder cancer	0.000633	0.00112	CcSEcCtD
Dexmedetomidine—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000631	0.00111	CcSEcCtD
Dexmedetomidine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000626	0.0011	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000618	0.00109	CcSEcCtD
Dexmedetomidine—Dyspnoea—Etoposide—urinary bladder cancer	0.000613	0.00108	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000611	0.00108	CcSEcCtD
Dexmedetomidine—Somnolence—Etoposide—urinary bladder cancer	0.000611	0.00108	CcSEcCtD
Dexmedetomidine—Vomiting—Thiotepa—urinary bladder cancer	0.000608	0.00107	CcSEcCtD
Dexmedetomidine—Pneumonia—Epirubicin—urinary bladder cancer	0.000608	0.00107	CcSEcCtD
Dexmedetomidine—Rash—Thiotepa—urinary bladder cancer	0.000603	0.00107	CcSEcCtD
Dexmedetomidine—Dermatitis—Thiotepa—urinary bladder cancer	0.000603	0.00106	CcSEcCtD
Dexmedetomidine—Headache—Thiotepa—urinary bladder cancer	0.0006	0.00106	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000593	0.00105	CcSEcCtD
Dexmedetomidine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000593	0.00105	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000592	0.00105	CcSEcCtD
Dexmedetomidine—Constipation—Etoposide—urinary bladder cancer	0.000588	0.00104	CcSEcCtD
Dexmedetomidine—Pain—Etoposide—urinary bladder cancer	0.000588	0.00104	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000587	0.00104	CcSEcCtD
Dexmedetomidine—Haemoglobin—Methotrexate—urinary bladder cancer	0.000583	0.00103	CcSEcCtD
Dexmedetomidine—Haemorrhage—Methotrexate—urinary bladder cancer	0.00058	0.00102	CcSEcCtD
Dexmedetomidine—Nausea—Thiotepa—urinary bladder cancer	0.000568	0.001	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000566	0.001	CcSEcCtD
Dexmedetomidine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000566	0.000999	CcSEcCtD
Dexmedetomidine—Pneumonia—Doxorubicin—urinary bladder cancer	0.000562	0.000993	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000562	0.000992	CcSEcCtD
Dexmedetomidine—Visual impairment—Methotrexate—urinary bladder cancer	0.000559	0.000986	CcSEcCtD
Dexmedetomidine—Bradycardia—Epirubicin—urinary bladder cancer	0.000552	0.000975	CcSEcCtD
Dexmedetomidine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000551	0.000973	CcSEcCtD
Dexmedetomidine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000548	0.000968	CcSEcCtD
Dexmedetomidine—Haemoglobin—Epirubicin—urinary bladder cancer	0.000545	0.000962	CcSEcCtD
Dexmedetomidine—Abdominal pain—Etoposide—urinary bladder cancer	0.000543	0.000959	CcSEcCtD
Dexmedetomidine—Body temperature increased—Etoposide—urinary bladder cancer	0.000543	0.000959	CcSEcCtD
Dexmedetomidine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000543	0.000959	CcSEcCtD
Dexmedetomidine—Haemorrhage—Epirubicin—urinary bladder cancer	0.000542	0.000958	CcSEcCtD
Dexmedetomidine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000542	0.000956	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000538	0.00095	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000534	0.000943	CcSEcCtD
Dexmedetomidine—Angiopathy—Methotrexate—urinary bladder cancer	0.000526	0.000928	CcSEcCtD
Dexmedetomidine—Dizziness—Fluorouracil—urinary bladder cancer	0.000523	0.000924	CcSEcCtD
Dexmedetomidine—Visual impairment—Epirubicin—urinary bladder cancer	0.000523	0.000923	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000522	0.000922	CcSEcCtD
Dexmedetomidine—Chills—Methotrexate—urinary bladder cancer	0.00052	0.000918	CcSEcCtD
Dexmedetomidine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000513	0.000906	CcSEcCtD
Dexmedetomidine—Vomiting—Gemcitabine—urinary bladder cancer	0.000512	0.000904	CcSEcCtD
Dexmedetomidine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000511	0.000902	CcSEcCtD
Dexmedetomidine—Mental disorder—Methotrexate—urinary bladder cancer	0.000508	0.000897	CcSEcCtD
Dexmedetomidine—Rash—Gemcitabine—urinary bladder cancer	0.000508	0.000896	CcSEcCtD
Dexmedetomidine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000507	0.000895	CcSEcCtD
Dexmedetomidine—Malnutrition—Methotrexate—urinary bladder cancer	0.000505	0.000891	CcSEcCtD
Dexmedetomidine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000504	0.000891	CcSEcCtD
Dexmedetomidine—Headache—Gemcitabine—urinary bladder cancer	0.000504	0.00089	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000503	0.000889	CcSEcCtD
Dexmedetomidine—Vomiting—Fluorouracil—urinary bladder cancer	0.000503	0.000889	CcSEcCtD
Dexmedetomidine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000502	0.000886	CcSEcCtD
Dexmedetomidine—Rash—Fluorouracil—urinary bladder cancer	0.000499	0.000881	CcSEcCtD
Dexmedetomidine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000499	0.00088	CcSEcCtD
Dexmedetomidine—Headache—Fluorouracil—urinary bladder cancer	0.000496	0.000876	CcSEcCtD
Dexmedetomidine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000494	0.000873	CcSEcCtD
Dexmedetomidine—Angiopathy—Epirubicin—urinary bladder cancer	0.000492	0.000869	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000489	0.000863	CcSEcCtD
Dexmedetomidine—Chills—Epirubicin—urinary bladder cancer	0.000487	0.000859	CcSEcCtD
Dexmedetomidine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000485	0.000855	CcSEcCtD
Dexmedetomidine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000484	0.000854	CcSEcCtD
Dexmedetomidine—Nausea—Gemcitabine—urinary bladder cancer	0.000478	0.000844	CcSEcCtD
Dexmedetomidine—Vomiting—Cisplatin—urinary bladder cancer	0.000477	0.000842	CcSEcCtD
Dexmedetomidine—Mental disorder—Epirubicin—urinary bladder cancer	0.000475	0.000839	CcSEcCtD
Dexmedetomidine—Rash—Cisplatin—urinary bladder cancer	0.000473	0.000835	CcSEcCtD
Dexmedetomidine—Dermatitis—Cisplatin—urinary bladder cancer	0.000473	0.000835	CcSEcCtD
Dexmedetomidine—Malnutrition—Epirubicin—urinary bladder cancer	0.000472	0.000834	CcSEcCtD
Dexmedetomidine—Diarrhoea—Etoposide—urinary bladder cancer	0.00047	0.00083	CcSEcCtD
Dexmedetomidine—Nausea—Fluorouracil—urinary bladder cancer	0.00047	0.00083	CcSEcCtD
Dexmedetomidine—Anaemia—Methotrexate—urinary bladder cancer	0.000466	0.000823	CcSEcCtD
Dexmedetomidine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000466	0.000822	CcSEcCtD
Dexmedetomidine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000455	0.000804	CcSEcCtD
Dexmedetomidine—Dizziness—Etoposide—urinary bladder cancer	0.000455	0.000803	CcSEcCtD
Dexmedetomidine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000452	0.000799	CcSEcCtD
Dexmedetomidine—Chills—Doxorubicin—urinary bladder cancer	0.00045	0.000795	CcSEcCtD
Dexmedetomidine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000448	0.000792	CcSEcCtD
Dexmedetomidine—Nausea—Cisplatin—urinary bladder cancer	0.000446	0.000787	CcSEcCtD
Dexmedetomidine—Mental disorder—Doxorubicin—urinary bladder cancer	0.00044	0.000776	CcSEcCtD
Dexmedetomidine—Convulsion—Methotrexate—urinary bladder cancer	0.000437	0.000772	CcSEcCtD
Dexmedetomidine—Vomiting—Etoposide—urinary bladder cancer	0.000437	0.000772	CcSEcCtD
Dexmedetomidine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000437	0.000771	CcSEcCtD
Dexmedetomidine—Anaemia—Epirubicin—urinary bladder cancer	0.000436	0.000771	CcSEcCtD
Dexmedetomidine—Agitation—Epirubicin—urinary bladder cancer	0.000434	0.000766	CcSEcCtD
Dexmedetomidine—Rash—Etoposide—urinary bladder cancer	0.000433	0.000765	CcSEcCtD
Dexmedetomidine—Dermatitis—Etoposide—urinary bladder cancer	0.000433	0.000765	CcSEcCtD
Dexmedetomidine—Headache—Etoposide—urinary bladder cancer	0.000431	0.00076	CcSEcCtD
Dexmedetomidine—Confusional state—Methotrexate—urinary bladder cancer	0.000415	0.000733	CcSEcCtD
Dexmedetomidine—Convulsion—Epirubicin—urinary bladder cancer	0.000409	0.000722	CcSEcCtD
Dexmedetomidine—Infection—Methotrexate—urinary bladder cancer	0.000409	0.000722	CcSEcCtD
Dexmedetomidine—Nausea—Etoposide—urinary bladder cancer	0.000408	0.000721	CcSEcCtD
Dexmedetomidine—Hypertension—Epirubicin—urinary bladder cancer	0.000408	0.00072	CcSEcCtD
Dexmedetomidine—Anaemia—Doxorubicin—urinary bladder cancer	0.000404	0.000713	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000403	0.000712	CcSEcCtD
Dexmedetomidine—Agitation—Doxorubicin—urinary bladder cancer	0.000401	0.000709	CcSEcCtD
Dexmedetomidine—Anxiety—Epirubicin—urinary bladder cancer	0.000401	0.000707	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000398	0.000703	CcSEcCtD
Dexmedetomidine—Dry mouth—Epirubicin—urinary bladder cancer	0.000393	0.000694	CcSEcCtD
Dexmedetomidine—Confusional state—Epirubicin—urinary bladder cancer	0.000389	0.000686	CcSEcCtD
Dexmedetomidine—Hypotension—Methotrexate—urinary bladder cancer	0.000385	0.000679	CcSEcCtD
Dexmedetomidine—Infection—Epirubicin—urinary bladder cancer	0.000383	0.000676	CcSEcCtD
Dexmedetomidine—Convulsion—Doxorubicin—urinary bladder cancer	0.000379	0.000668	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000377	0.000666	CcSEcCtD
Dexmedetomidine—Hypertension—Doxorubicin—urinary bladder cancer	0.000377	0.000666	CcSEcCtD
Dexmedetomidine—Tachycardia—Epirubicin—urinary bladder cancer	0.000376	0.000664	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000373	0.000658	CcSEcCtD
Dexmedetomidine—Anxiety—Doxorubicin—urinary bladder cancer	0.000371	0.000654	CcSEcCtD
Dexmedetomidine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000367	0.000648	CcSEcCtD
Dexmedetomidine—Somnolence—Methotrexate—urinary bladder cancer	0.000366	0.000646	CcSEcCtD
Dexmedetomidine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000364	0.000642	CcSEcCtD
Dexmedetomidine—Hypotension—Epirubicin—urinary bladder cancer	0.00036	0.000636	CcSEcCtD
Dexmedetomidine—Confusional state—Doxorubicin—urinary bladder cancer	0.000359	0.000635	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000355	0.000628	CcSEcCtD
Dexmedetomidine—Infection—Doxorubicin—urinary bladder cancer	0.000354	0.000625	CcSEcCtD
Dexmedetomidine—Pain—Methotrexate—urinary bladder cancer	0.000352	0.000622	CcSEcCtD
Dexmedetomidine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000349	0.000616	CcSEcCtD
Dexmedetomidine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000348	0.000614	CcSEcCtD
Dexmedetomidine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000345	0.000609	CcSEcCtD
Dexmedetomidine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000344	0.000607	CcSEcCtD
Dexmedetomidine—Somnolence—Epirubicin—urinary bladder cancer	0.000343	0.000605	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000339	0.000599	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000337	0.000594	CcSEcCtD
Dexmedetomidine—Hypotension—Doxorubicin—urinary bladder cancer	0.000333	0.000588	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000333	0.000587	CcSEcCtD
Dexmedetomidine—Pain—Epirubicin—urinary bladder cancer	0.00033	0.000582	CcSEcCtD
Dexmedetomidine—Constipation—Epirubicin—urinary bladder cancer	0.00033	0.000582	CcSEcCtD
Dexmedetomidine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000325	0.000575	CcSEcCtD
Dexmedetomidine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000325	0.000575	CcSEcCtD
Dexmedetomidine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000318	0.000561	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000318	0.000561	CcSEcCtD
Dexmedetomidine—Somnolence—Doxorubicin—urinary bladder cancer	0.000317	0.00056	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000315	0.000556	CcSEcCtD
Dexmedetomidine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000308	0.000543	CcSEcCtD
Dexmedetomidine—Pain—Doxorubicin—urinary bladder cancer	0.000305	0.000538	CcSEcCtD
Dexmedetomidine—Constipation—Doxorubicin—urinary bladder cancer	0.000305	0.000538	CcSEcCtD
Dexmedetomidine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000305	0.000538	CcSEcCtD
Dexmedetomidine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000305	0.000538	CcSEcCtD
Dexmedetomidine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000294	0.000519	CcSEcCtD
Dexmedetomidine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000292	0.000515	CcSEcCtD
Dexmedetomidine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000282	0.000498	CcSEcCtD
Dexmedetomidine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000282	0.000498	CcSEcCtD
Dexmedetomidine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000282	0.000497	CcSEcCtD
Dexmedetomidine—Dizziness—Methotrexate—urinary bladder cancer	0.000272	0.000481	CcSEcCtD
Dexmedetomidine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000264	0.000466	CcSEcCtD
Dexmedetomidine—Vomiting—Methotrexate—urinary bladder cancer	0.000262	0.000462	CcSEcCtD
Dexmedetomidine—Rash—Methotrexate—urinary bladder cancer	0.00026	0.000458	CcSEcCtD
Dexmedetomidine—Dermatitis—Methotrexate—urinary bladder cancer	0.000259	0.000458	CcSEcCtD
Dexmedetomidine—Headache—Methotrexate—urinary bladder cancer	0.000258	0.000455	CcSEcCtD
Dexmedetomidine—Dizziness—Epirubicin—urinary bladder cancer	0.000255	0.00045	CcSEcCtD
Dexmedetomidine—Vomiting—Epirubicin—urinary bladder cancer	0.000245	0.000433	CcSEcCtD
Dexmedetomidine—Nausea—Methotrexate—urinary bladder cancer	0.000245	0.000432	CcSEcCtD
Dexmedetomidine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000244	0.000431	CcSEcCtD
Dexmedetomidine—Rash—Epirubicin—urinary bladder cancer	0.000243	0.000429	CcSEcCtD
Dexmedetomidine—Dermatitis—Epirubicin—urinary bladder cancer	0.000243	0.000429	CcSEcCtD
Dexmedetomidine—Headache—Epirubicin—urinary bladder cancer	0.000241	0.000426	CcSEcCtD
Dexmedetomidine—Dizziness—Doxorubicin—urinary bladder cancer	0.000236	0.000416	CcSEcCtD
Dexmedetomidine—Nausea—Epirubicin—urinary bladder cancer	0.000229	0.000404	CcSEcCtD
Dexmedetomidine—Vomiting—Doxorubicin—urinary bladder cancer	0.000227	0.0004	CcSEcCtD
Dexmedetomidine—Rash—Doxorubicin—urinary bladder cancer	0.000225	0.000397	CcSEcCtD
Dexmedetomidine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000225	0.000397	CcSEcCtD
Dexmedetomidine—Headache—Doxorubicin—urinary bladder cancer	0.000223	0.000394	CcSEcCtD
Dexmedetomidine—Nausea—Doxorubicin—urinary bladder cancer	0.000212	0.000374	CcSEcCtD
Dexmedetomidine—ADRA2A—Signaling Pathways—TSC1—urinary bladder cancer	4.98e-05	0.000278	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NQO1—urinary bladder cancer	4.95e-05	0.000276	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—RHOA—urinary bladder cancer	4.94e-05	0.000276	CbGpPWpGaD
Dexmedetomidine—ADRA1D—GPCR downstream signaling—IL2—urinary bladder cancer	4.91e-05	0.000274	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.9e-05	0.000274	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—GPX1—urinary bladder cancer	4.87e-05	0.000272	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—RHOA—urinary bladder cancer	4.86e-05	0.000271	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—RHOA—urinary bladder cancer	4.8e-05	0.000268	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—ERCC2—urinary bladder cancer	4.78e-05	0.000267	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—EP300—urinary bladder cancer	4.78e-05	0.000267	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—JAG1—urinary bladder cancer	4.74e-05	0.000265	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—KRAS—urinary bladder cancer	4.74e-05	0.000265	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—S100B—urinary bladder cancer	4.73e-05	0.000264	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	4.7e-05	0.000263	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—CXCL8—urinary bladder cancer	4.67e-05	0.000261	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NQO1—urinary bladder cancer	4.67e-05	0.000261	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—S100B—urinary bladder cancer	4.65e-05	0.00026	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—SRC—urinary bladder cancer	4.65e-05	0.000259	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.64e-05	0.000259	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	4.62e-05	0.000258	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—NCOR1—urinary bladder cancer	4.55e-05	0.000254	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.53e-05	0.000253	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—TP53—urinary bladder cancer	4.51e-05	0.000252	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTP1—urinary bladder cancer	4.5e-05	0.000251	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—MTHFR—urinary bladder cancer	4.49e-05	0.000251	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—RHOA—urinary bladder cancer	4.48e-05	0.00025	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—IL2—urinary bladder cancer	4.46e-05	0.000249	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TERT—urinary bladder cancer	4.44e-05	0.000248	CbGpPWpGaD
Dexmedetomidine—ADRA2B—GPCR downstream signaling—IL2—urinary bladder cancer	4.43e-05	0.000248	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—RHOA—urinary bladder cancer	4.41e-05	0.000246	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	4.36e-05	0.000243	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	4.36e-05	0.000243	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.33e-05	0.000242	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Hemostasis—HRAS—urinary bladder cancer	4.31e-05	0.000241	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.27e-05	0.000238	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—NCOR1—urinary bladder cancer	4.25e-05	0.000238	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	4.23e-05	0.000236	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—CXCL8—urinary bladder cancer	4.21e-05	0.000235	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—TP53—urinary bladder cancer	4.21e-05	0.000235	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—NCOR1—urinary bladder cancer	4.19e-05	0.000234	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—TYMS—urinary bladder cancer	4.18e-05	0.000233	CbGpPWpGaD
Dexmedetomidine—ADRA2C—GPCR downstream signaling—IL2—urinary bladder cancer	4.14e-05	0.000231	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GSTM1—urinary bladder cancer	4.13e-05	0.000231	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—NCOR1—urinary bladder cancer	4.13e-05	0.000231	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	4.13e-05	0.000231	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—FGFR3—urinary bladder cancer	4.08e-05	0.000228	CbGpPWpGaD
Dexmedetomidine—ADRA1B—GPCR downstream signaling—IL2—urinary bladder cancer	4.08e-05	0.000228	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—IL2—urinary bladder cancer	4.03e-05	0.000225	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Hemostasis—HRAS—urinary bladder cancer	4.03e-05	0.000225	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TERT—urinary bladder cancer	4.01e-05	0.000224	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	4.01e-05	0.000224	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	3.99e-05	0.000223	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ESR1—urinary bladder cancer	3.96e-05	0.000221	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—GPX1—urinary bladder cancer	3.96e-05	0.000221	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.95e-05	0.000221	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—CXCL8—urinary bladder cancer	3.94e-05	0.00022	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	3.89e-05	0.000217	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—ERCC2—urinary bladder cancer	3.88e-05	0.000217	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—CXCL8—urinary bladder cancer	3.87e-05	0.000216	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—KRAS—urinary bladder cancer	3.85e-05	0.000215	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—S100B—urinary bladder cancer	3.84e-05	0.000215	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—TYMS—urinary bladder cancer	3.84e-05	0.000214	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	3.79e-05	0.000212	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	3.79e-05	0.000212	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.77e-05	0.00021	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—IL2—urinary bladder cancer	3.76e-05	0.00021	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TERT—urinary bladder cancer	3.75e-05	0.000209	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—IL2—urinary bladder cancer	3.7e-05	0.000207	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	3.69e-05	0.000206	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	3.69e-05	0.000206	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TERT—urinary bladder cancer	3.69e-05	0.000206	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—FGFR3—urinary bladder cancer	3.68e-05	0.000206	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.67e-05	0.000205	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—MTHFR—urinary bladder cancer	3.65e-05	0.000204	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PPARG—urinary bladder cancer	3.64e-05	0.000204	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—RHOA—urinary bladder cancer	3.64e-05	0.000203	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—GPX1—urinary bladder cancer	3.63e-05	0.000203	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—TYMS—urinary bladder cancer	3.62e-05	0.000202	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	3.58e-05	0.0002	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	3.58e-05	0.0002	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	3.58e-05	0.0002	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ESR1—urinary bladder cancer	3.58e-05	0.0002	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	3.57e-05	0.000199	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.53e-05	0.000197	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	3.52e-05	0.000197	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.51e-05	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—CREBBP—urinary bladder cancer	3.5e-05	0.000196	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CREBBP—urinary bladder cancer	3.47e-05	0.000194	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	3.45e-05	0.000193	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—FGFR3—urinary bladder cancer	3.44e-05	0.000192	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IGF1—urinary bladder cancer	3.43e-05	0.000191	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—GPX1—urinary bladder cancer	3.42e-05	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—TP53—urinary bladder cancer	3.42e-05	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—EGFR—urinary bladder cancer	3.41e-05	0.000191	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—FGFR3—urinary bladder cancer	3.39e-05	0.000189	CbGpPWpGaD
Dexmedetomidine—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	3.36e-05	0.000188	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	3.36e-05	0.000188	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	3.35e-05	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ESR1—urinary bladder cancer	3.34e-05	0.000187	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ESR1—urinary bladder cancer	3.29e-05	0.000184	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	3.27e-05	0.000183	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—KRAS—urinary bladder cancer	3.22e-05	0.00018	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	3.2e-05	0.000179	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	3.16e-05	0.000177	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—RHOA—urinary bladder cancer	3.14e-05	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CREBBP—urinary bladder cancer	3.13e-05	0.000175	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IGF1—urinary bladder cancer	3.1e-05	0.000173	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—EGFR—urinary bladder cancer	3.08e-05	0.000172	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	3.06e-05	0.000171	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	3.04e-05	0.00017	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.98e-05	0.000166	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PPARG—urinary bladder cancer	2.96e-05	0.000165	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.93e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CREBBP—urinary bladder cancer	2.93e-05	0.000164	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—KRAS—urinary bladder cancer	2.91e-05	0.000163	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—ERBB2—urinary bladder cancer	2.91e-05	0.000162	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IGF1—urinary bladder cancer	2.89e-05	0.000161	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.89e-05	0.000161	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	2.88e-05	0.000161	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—EGFR—urinary bladder cancer	2.88e-05	0.000161	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTGS2—urinary bladder cancer	2.87e-05	0.00016	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	2.85e-05	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	2.84e-05	0.000159	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—RHOA—urinary bladder cancer	2.84e-05	0.000158	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	2.83e-05	0.000158	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	2.79e-05	0.000156	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CXCL8—urinary bladder cancer	2.76e-05	0.000154	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling by GPCR—HRAS—urinary bladder cancer	2.74e-05	0.000153	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.72e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PPARG—urinary bladder cancer	2.72e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—KRAS—urinary bladder cancer	2.72e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	2.71e-05	0.000152	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.69e-05	0.00015	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.69e-05	0.00015	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	2.67e-05	0.000149	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—RHOA—urinary bladder cancer	2.65e-05	0.000148	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—IL2—urinary bladder cancer	2.64e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	2.62e-05	0.000147	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	2.61e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	2.61e-05	0.000146	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.58e-05	0.000144	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CCND1—urinary bladder cancer	2.57e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PPARG—urinary bladder cancer	2.56e-05	0.000143	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.53e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.52e-05	0.000141	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—PTEN—urinary bladder cancer	2.5e-05	0.00014	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MMP9—urinary bladder cancer	2.49e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	2.49e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—CDKN1A—urinary bladder cancer	2.48e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.48e-05	0.000139	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—PTEN—urinary bladder cancer	2.48e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	2.47e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	2.46e-05	0.000138	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	2.45e-05	0.000137	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	2.41e-05	0.000135	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.4e-05	0.000134	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Metabolism—EP300—urinary bladder cancer	2.38e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.38e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	2.38e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	2.38e-05	0.000133	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EP300—urinary bladder cancer	2.36e-05	0.000132	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	2.35e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	2.34e-05	0.000131	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	2.33e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	2.33e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	2.32e-05	0.00013	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	2.31e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.31e-05	0.000129	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—SRC—urinary bladder cancer	2.3e-05	0.000128	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	2.29e-05	0.000128	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.28e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.28e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	2.27e-05	0.000127	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	2.25e-05	0.000126	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	2.24e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	2.24e-05	0.000125	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	2.22e-05	0.000124	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	2.21e-05	0.000123	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	2.19e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.18e-05	0.000122	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	2.17e-05	0.000121	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	2.15e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.14e-05	0.00012	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	2.14e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	2.13e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	2.13e-05	0.000119	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	2.1e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	2.1e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	2.09e-05	0.000117	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	2.08e-05	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	2.07e-05	0.000116	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	2.06e-05	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—MYC—urinary bladder cancer	2.06e-05	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	2.06e-05	0.000115	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	2.03e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	2.02e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.02e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—EGFR—urinary bladder cancer	2.02e-05	0.000113	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	1.99e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.99e-05	0.000111	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	1.96e-05	0.00011	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	1.94e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Metabolism—EP300—urinary bladder cancer	1.94e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.93e-05	0.000108	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	1.91e-05	0.000107	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—KRAS—urinary bladder cancer	1.9e-05	0.000106	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.89e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.88e-05	0.000105	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.87e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	1.86e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.85e-05	0.000104	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	1.82e-05	0.000102	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	1.8e-05	0.000101	CbGpPWpGaD
Dexmedetomidine—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.78e-05	9.93e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.76e-05	9.83e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—PTEN—urinary bladder cancer	1.76e-05	9.82e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	1.74e-05	9.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	1.72e-05	9.6e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	1.71e-05	9.55e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.71e-05	9.54e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.7e-05	9.51e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	1.7e-05	9.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.7e-05	9.49e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—TP53—urinary bladder cancer	1.69e-05	9.45e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A1—Metabolism—EP300—urinary bladder cancer	1.68e-05	9.37e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	1.67e-05	9.34e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.63e-05	9.13e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	1.62e-05	9.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1D—Signaling Pathways—HRAS—urinary bladder cancer	1.62e-05	9.04e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	1.61e-05	8.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	1.58e-05	8.83e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	1.57e-05	8.8e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.57e-05	8.77e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	1.53e-05	8.53e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.52e-05	8.48e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	1.46e-05	8.16e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	1.43e-05	7.97e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	1.41e-05	7.88e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	1.4e-05	7.84e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	1.38e-05	7.71e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	1.36e-05	7.62e-05	CbGpPWpGaD
Dexmedetomidine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	1.34e-05	7.5e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.32e-05	7.39e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	1.3e-05	7.28e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.29e-05	7.18e-05	CbGpPWpGaD
Dexmedetomidine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.26e-05	7.05e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	1.16e-05	6.47e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.12e-05	6.26e-05	CbGpPWpGaD
Dexmedetomidine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	1.11e-05	6.19e-05	CbGpPWpGaD
Dexmedetomidine—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.07e-05	5.97e-05	CbGpPWpGaD
